IMPACT Therapeutics, Inc. disclosed on 4 November 2026 that its board has approved an on-market repurchase of H shares on the Hong Kong Stock Exchange for an aggregate consideration of up to HK$100.00 million, inclusive of brokerage commission and stamp duty.
The programme will be executed under the general mandate granted by shareholders at the 25 June 2026 AGM. The mandate remains valid until the earlier of: 1) the conclusion of the next AGM, 2) the deadline by which the next AGM must be held under PRC law and the company’s articles, or 3) a shareholder resolution revoking or varying the authority.
Key parameters and intentions: • Funding source: internal financial resources excluding proceeds from the global offering. • Objective: protect corporate value and shareholder interests, while signalling confidence in business prospects. • Execution: repurchases will be conducted in compliance with the Hong Kong Listing Rules, the Codes on Takeovers and Share Buy-backs, PRC laws and the company’s articles. Repurchased shares will be cancelled or held in treasury as deemed appropriate, ensuring public float requirements are maintained. • Status: no H shares had been repurchased under the mandate as of the announcement date.
The board emphasised that the scale, timing and price of any buyback depend on prevailing market conditions and remain at the directors’ discretion. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.
Comments